Its additional ability to interact with Cldn5 is of advantage for potential NSCLC treatment, since NSCLC is characterized by upregulation of several claudins including both Cldn1 and Cldn5 (Paschoud et al., 2007). The gene discussed is CLDN1; the disease is non-small cell lung carcinoma.